Eight important updates for World Thrombosis Day

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

World Thrombosis Day is observed on Oct. 13.

The annual observance — now in its sixth year — is part of a campaign to raise awareness about the condition, including its causes, risk factors, symptoms, and prevention and treatment strategies.

In conjunction with World Thrombosis Day, HemOnc Today and Healio highlight eight research updates in thrombosis treatment, surveillance and risk prediction.

• Direct oral anticoagulants should be used to prevent venous thromboembolism among certain patients with cancer, as well as to treat those who develop blood clots, according to updated ASCO recommendations. Read more.
• Higher estimated cardiorespiratory fitness levels appeared associated with a lower risk for VTE. Read more.
• VTE risk factors appeared highly prevalent among postpartum women at a Dublin hospital. Read more.
• Extended treatment with oral edoxaban (Savaysa, Daiichi Sankyo) appeared comparable to subcutaneous dalteparin in safety and effectiveness for prevention of recurrent VTE and major bleeding among patients with active cancer. Read more.
• Placing an inferior vena cava filter in patients within 72 hours of major trauma did not reduce incidence of symptomatic pulmonary embolism or death at 90 days. Read more.
• Rivaroxaban (Xarelto, Janssen) thromboprophylaxis greatly reduced VTE among ambulatory patients with pancreatic cancer. Read more.
• ASH collaborated with the McMaster University GRADE Centre to develop clinical practice guidelines on VTE. This cover story reviews the first six chapters of the guidelines, addresses the complexities of VTE prophylaxis and treatment, and highlights the need for more guidance about management of specific patient populations. Read more.
• In this installment of Point/Counter, two clinicians debate whether heparin eventually be phased out due to expanded use of direct oral anticoagulants. Read more.